What are the recommended indications, dosing, and monitoring parameters for using bicalutamide in transgender women receiving feminizing estrogen therapy?

Bicalutamide Use in Transgender Women

Bicalutamide is NOT recommended as a standard antiandrogen for transgender women based on current FDA approval and established guidelines, though emerging evidence suggests it may be considered as an alternative when GnRH analogs or spironolactone are unavailable or contraindicated.

FDA-Approved Indication and Off-Label Use

• Bicalutamide 50 mg daily is FDA-approved only for Stage D2 metastatic prostate cancer in combination with LHRH analogs 1
• The 150 mg dose is explicitly not approved for use alone or with other treatments 1
• Use in transgender women is entirely off-label and not mentioned in the 2009 Endocrine Society guidelines for transgender care 2

Dosing When Used Off-Label

Based on emerging research in transgender populations:

• Most commonly used dose: 25-50 mg daily 3, 4, 5
• The FDA-approved 50 mg daily dose for prostate cancer appears to be the upper limit used in transgender care 1
• Lower doses (25 mg) may be sufficient given the median dose in one case series was 25 mg daily 3
• Timing: Once daily, morning or evening, with or without food 1

Critical Monitoring Requirements

Hepatic Monitoring (Mandatory)

Bicalutamide carries a black box concern for severe hepatotoxicity, including fatal hepatic failure 1:

• Measure serum transaminases (especially ALT) before starting treatment 1
• Monitor liver function tests at regular intervals for the first 4 months 1
• Continue periodic monitoring thereafter 1
• Immediately discontinue if ALT rises above 2× upper limit of normal or if jaundice develops 1
• Most hepatotoxicity occurs within the first 3-4 months of treatment 1
• In transgender youth and adults studied, no episodes of liver toxicity were observed, though follow-up was limited 3, 4

Testosterone Monitoring

• Serum total testosterone will NOT suppress to female ranges with bicalutamide monotherapy 3
• Median testosterone was 7.7 nmol/L (range 0.7-17.5) in one case series—well above cisgender female ranges 3
• This is expected because bicalutamide is a pure androgen receptor antagonist, not a testosterone suppressor 3
• Traditional guideline targets for testosterone suppression (<55 ng/dL) are inappropriate when using bicalutamide 3
• LH levels may remain elevated (median 2.9 IU/L) 3

Additional Monitoring

• No specific estradiol monitoring requirements unique to bicalutamide beyond standard feminizing hormone therapy monitoring 2
• Monitor for gynecomastia and breast pain (common with 150 mg dose as monotherapy) 1
• Standard cardiovascular risk factor monitoring as with any feminizing therapy 2

Clinical Efficacy Considerations

Feminization Effects

• 84-90% of patients reported breast development within 6-7 months, with majority achieving Tanner stage III or greater 4, 5
• This occurred even with bicalutamide monotherapy (without estrogen) 4, 5
• Breast development may occur through peripheral aromatization of unsuppressed testosterone 4, 5

Treatment Discontinuation

• In one series, 6 of 24 patients (25%) discontinued bicalutamide due to lack of perceived benefit 3
• This suggests variable patient satisfaction with this approach 3

Key Contraindications and Warnings

• Absolutely contraindicated in pregnancy (can cause fetal harm) 1
• Contraindicated in patients with hypersensitivity to bicalutamide 1
• Use extreme caution or avoid in patients with pre-existing liver disease 1
• If used with coumarin anticoagulants, closely monitor PT/INR 1
• Bicalutamide inhibits CYP3A4; caution with CYP3A4 substrates 1

Clinical Context and Limitations

The 2009 Endocrine Society guidelines do not mention bicalutamide as an option for transgender care 2. The guidelines focus on:

• GnRH analogs for gonadotropin suppression 2
• Spironolactone as the implied standard antiandrogen (though not explicitly detailed in provided excerpts)
• Maintaining testosterone in female ranges (<55 ng/dL) 2

Bicalutamide appears in recent literature primarily as a second-line option when:

• Insurance denies GnRH analogs 5
• Other antiandrogens are contraindicated or poorly tolerated 3, 4
• Patients are ready for physical transition and breast development is desired 5

Practical Algorithm for Consideration

IF considering bicalutamide (recognizing this is off-label):

1. Confirm patient understands this is off-label use with limited long-term safety data
2. Obtain baseline ALT, AST, and complete liver function panel
3. Start at 25 mg daily (lower end of reported range) 3
4. Monitor ALT/AST monthly for first 4 months, then every 3-6 months 1
5. Discontinue immediately if ALT >2× ULN or any signs of hepatotoxicity 1
6. Do NOT expect testosterone suppression to female ranges—this is not the mechanism of action 3
7. Counsel that 25% may discontinue due to inadequate perceived benefit 3
8. Consider adding or transitioning to estrogen for additional feminization 4, 5